JP2025513850A5 - - Google Patents

Info

Publication number
JP2025513850A5
JP2025513850A5 JP2024560404A JP2024560404A JP2025513850A5 JP 2025513850 A5 JP2025513850 A5 JP 2025513850A5 JP 2024560404 A JP2024560404 A JP 2024560404A JP 2024560404 A JP2024560404 A JP 2024560404A JP 2025513850 A5 JP2025513850 A5 JP 2025513850A5
Authority
JP
Japan
Prior art keywords
capsid
irak
pharmaceutical composition
aav
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065687 external-priority patent/WO2023201272A1/en
Publication of JP2025513850A publication Critical patent/JP2025513850A/ja
Publication of JP2025513850A5 publication Critical patent/JP2025513850A5/ja
Pending legal-status Critical Current

Links

JP2024560404A 2022-04-12 2023-04-12 遺伝子治療のためのirak4モジュレーターの使用 Pending JP2025513850A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263330239P 2022-04-12 2022-04-12
US63/330,239 2022-04-12
PCT/US2023/065687 WO2023201272A1 (en) 2022-04-12 2023-04-12 Use of irak4 modulators for gene therapy

Publications (2)

Publication Number Publication Date
JP2025513850A JP2025513850A (ja) 2025-04-30
JP2025513850A5 true JP2025513850A5 (OSRAM) 2026-04-20

Family

ID=86329443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560404A Pending JP2025513850A (ja) 2022-04-12 2023-04-12 遺伝子治療のためのirak4モジュレーターの使用

Country Status (11)

Country Link
US (1) US20230405151A1 (OSRAM)
EP (1) EP4508225A1 (OSRAM)
JP (1) JP2025513850A (OSRAM)
KR (1) KR20250004740A (OSRAM)
CN (1) CN119630802A (OSRAM)
AU (1) AU2023252915A1 (OSRAM)
CA (1) CA3248481A1 (OSRAM)
IL (1) IL316231A (OSRAM)
MX (1) MX2024012616A (OSRAM)
TW (1) TW202400250A (OSRAM)
WO (1) WO2023201272A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4072591A4 (en) 2019-12-10 2024-06-05 Kymera Therapeutics, Inc. IRAQ DEGRADER AND USES THEREOF
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア T7ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP2369002A1 (en) 1999-08-09 2011-09-28 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
US7261544B2 (en) 2003-05-21 2007-08-28 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US20100279316A1 (en) 2007-01-19 2010-11-04 Leonid Gorelik Antibodies to Phosphorylated IRAK4
KR101812813B1 (ko) 2009-06-16 2017-12-27 젠자임 코포레이션 재조합 aav 벡터에 대한 개선된 정제 방법
US20110070241A1 (en) * 2009-06-30 2011-03-24 Duke University Methods for modulating immune responses to aav gene therapy vectors
EP3567106A1 (en) 2010-04-23 2019-11-13 University of Massachusetts Cns targeting aav vectors and methods of use thereof
CN106413715A (zh) 2014-04-22 2017-02-15 林伯士艾瑞斯公司 Irak抑制剂和其用途
EP3200788B1 (en) 2014-09-30 2019-09-18 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US10040798B2 (en) 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of IRAK4 activity
WO2017004133A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
US10988482B2 (en) 2015-08-13 2021-04-27 Beijing Hanmi Pharmaceutical Co., Ltd. IRAK4 inhibitor and use thereof
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
MX2020009234A (es) 2018-04-05 2020-10-12 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
AU2019294836B2 (en) 2018-06-29 2024-06-20 Dana-Farber Cancer Institute, Inc. Bispecific degraders
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
WO2020264490A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US12528814B2 (en) 2020-02-19 2026-01-20 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
WO2021231575A1 (en) * 2020-05-12 2021-11-18 Myogene Bio Llc Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型

Similar Documents

Publication Publication Date Title
US20210285012A1 (en) Method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
CN108602859B (zh) 增强细小病毒载体递送的修饰衣壳蛋白
CN102174574B (zh) 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
JP2024149508A (ja) 新規アデノ随伴ウイルス(aav)バリアント及び遺伝子治療のためのその使用
TW201629225A (zh) 第九因子基因療法
JP2025513851A5 (OSRAM)
JP2022545121A (ja) Aav5の単離修飾vp1カプシドタンパク質
CN111876432B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
TW202402329A (zh) Irak4調節劑於基因療法之用途(二)
US11077208B2 (en) Wilson's disease gene therapy
JP2023513932A (ja) X連鎖障害の治療におけるmiRNAのAAV媒介標的化
TW202405430A (zh) 對於基因療法藥劑的先天免疫原性之樹突細胞試驗
RU2024133631A (ru) Применение модуляторов irak4 для генной терапии
CA2756866E (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
Еpifanova et al. Viral Vectors for Delivering Gene Material into Cells and Their Application in Neurobiology
EA050477B1 (ru) Доставка альфа-саркогликана с помощью вектора на основе аденоассоциированного вируса и лечение мышечной дистрофии
HU230093B1 (hu) Eljárás adeno-asszociált vírus(AAV)szekvenciák detektálására és/vagy azonosítására, és az azzal azonosított új szekvenciák izolálására
HK1068925B (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
HK1260937B (en) Modified capsid proteins for enhanced delivery of parvovirus vectors